A Study of Lurasidone Compared With Placebo for the Treatment of Bipolar I Depression

Bipolar I Depression Clinical Trial

Official title:
A Randomized, 6-Week, Multicenter, Double-Blind, Placebo-Controlled, Flexible Dose, Parallel-Group Study of Lurasidone for the Treatment of Bipolar I Depression

Status Terminated

Clinical Trial Summary

The study evaluates the efficacy and safety of lurasidone compared with placebo in treating Bipolar I Depression.

Clinical Trial Description

The primary objective is to compare the efficacy of lurasidone (20-120 mg/day) monotherapy with that of placebo in patients with Bipolar I Depression by assessing the change from baseline in the MADRS total score at Week 6. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04383691
Study type	Interventional
Source	Sumitomo Pharma (Suzhou) Co., Ltd.
Contact
Status	Terminated
Phase	Phase 3
Start date	December 11, 2020
Completion date	December 23, 2022

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00812058` - A Study to Assess the Safety, Tolerability and Efficacy of RG2417 in Bipolar I Depression	Phase 2
Completed	`NCT02046369` - Lurasidone Pediatric Bipolar Study	Phase 3
Completed	`NCT00481195` - Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder	Phase 2
Completed	`NCT01403662` - Evaluating the Efficacy of Adjunctive Minocycline for the Treatment of Bipolar Depression	Phase 3
Recruiting	`NCT03336918` - Lithium Effects on the Brain's Functional and Structural Connectome in the Treatment of Bipolar Disorder